Doxorubicin Hydrochloride 50mg Injection

Doxorubicin Hydrochloride 50mg Injection is a potent anthracycline antibiotic that ranks among the most effective broad-spectrum antineoplastic agents ever developed. Often referred to as the “Red Devil” due to its vivid red color and powerful cytotoxicity, this medication attacks cancer cells through two primary mechanisms. First, it intercalates between DNA base pairs, disrupting the topoisomerase II enzyme. This prevents the DNA double helix from being resealed after replication, causing the strands to break and triggering cell death. Second, it generates free radicals that cause oxidative damage to cellular membranes and DNA. This dual-action approach makes it highly effective against rapidly dividing cells in a wide variety of tissues. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for treating solid tumors and hematologic malignancies, serving as the backbone of curative regimens for lymphoma, breast cancer, and sarcoma.

The 50mg vial strength is a versatile unit for preparing body surface area (BSA)-based dosages (typically 60-75 mg/m²). Doxorubicin Hydrochloride 50mg Injection is a vesicant, meaning it can cause severe tissue necrosis if it leaks out of the vein (extravasation). Therefore, it requires administration by skilled oncology nurses, often via a central line or a freshly inserted cannula with free-flowing saline. Its distinct red color will also turn the patient’s urine red for 1-2 days after administration, a harmless but startling effect known as “red urine.”

Indications / Uses of Doxorubicin Hydrochloride 50mg Injection

Doxorubicin Hydrochloride 50mg Injection is commonly prescribed for the specialized management of the following malignancies:

• Breast Cancer: It is a cornerstone of adjuvant and metastatic breast cancer therapy, typically used in combination with cyclophosphamide (AC regimen) or taxanes.
• Hodgkin’s and Non-Hodgkin’s Lymphoma: The medication is the “H” in the famous CHOP regimen and the “A” in the ABVD regimen, playing a critical role in curing lymphomas.
• Soft Tissue and Bone Sarcomas: It is one of the most active agents for treating osteosarcoma and Ewing’s sarcoma in both children and adults.
• Acute Leukemias: Doxorubicin is frequently used to treat Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML).
• Ovarian, Bladder, and Thyroid Cancers: It serves as a key component in multi-agent protocols for advanced stages of these solid tumors.

Key Features

• Broad-Spectrum Efficacy: The primary feature of Doxorubicin Hydrochloride 50mg Injection is its activity against a wider range of cancers than almost any other chemotherapy drug.
• Dual Mechanism of Action: It combines DNA intercalation with free radical generation to overcome tumor resistance.
• Curative Potential: It is a central component of curative regimens for lymphomas and adjuvant breast cancer.
• 50mg Vial Size: The 50mg strength allows for efficient compounding of standard adult doses while minimizing the number of vials needed.
• Rapid Cellular Uptake: The drug quickly penetrates tissues, providing an immediate cytotoxic effect.

Storage for Doxorubicin Hydrochloride 50mg Injection

To preserve the chemical stability and ultimate potency of the active ingredients, Doxorubicin Hydrochloride 50mg Injection should be stored under refrigeration, typically between 2°C and 8°C (36°F to 46°F). It is vital to keep the vial in its original carton to protect it from light, as the drug is light-sensitive. Do not freeze. Once diluted for infusion, the solution is stable for a limited time (often 24 hours at room temperature or 48 hours refrigerated), but immediate use is recommended to ensure microbiological safety. Store the medication in a secure, professional medical refrigerator strictly out of the reach of children.

Important Note on Doxorubicin Hydrochloride 50mg Injection

The administration of Doxorubicin Hydrochloride 50mg Injection is limited by its potential for Cumulative Cardiotoxicity. The drug can cause permanent damage to the heart muscle, leading to congestive heart failure. The risk increases significantly as the total lifetime dose approaches 450-550 mg/m². Therefore, an echocardiogram (ECHO) or MUGA scan to measure Left Ventricular Ejection Fraction (LVEF) is mandatory before starting treatment and periodically during therapy.

Extravasation Risk: If the drug leaks into surrounding tissue during infusion, it causes severe necrosis (tissue death) that can damage nerves and tendons, sometimes requiring skin grafts. If burning or stinging occurs, the infusion must be stopped immediately.

Myelosuppression (low white blood cells, platelets, anemia) is the major acute toxicity; blood counts must be monitored before every cycle. Severe nausea, vomiting, and complete hair loss (alopecia) are expected side effects. Doxorubicin Hydrochloride 50mg Injection can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and tracking the cumulative lifetime dose, healthcare providers can safely maximize the life-saving potential of Doxorubicin Hydrochloride 50mg Injection.